Glatiramer Acetate (GA) is a 1st line injectable Disease Modifying Drug therapy (DMD) for patients with relapsing forms of multiple sclerosis (RMS). Being the first follow-on product in the entire MS market Glatiramer Acetate is pioneering to change existing mindsets since end 2016 in 15 European countries with its therapeutically equivalent follow on GA. Reaching successful uptake requires changing of established prescription habits. The key message: say “YES” to Glatiramer Acetate, aligning to patient wellness and positive outcomes.
